Clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes

The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes
Read the complete summary
NICE has recommended insulin glargine as an option for people with type 1 diabetes. For people with type 2 diabetes who need to take insulin, NICE has recommended that insulin glargine should be an option only if the person:
needs help with his or her insulin injections from a carer or healthcare professional, or
has repeated and unpleasant hypoglycaemic episodes that significantly affect his or her way of life, or would otherwise need to have two insulin injections to maintain background levels every day as well as having to take other diabetes medicines orally.

The recommendations in this technology appraisal relating to type 2 diabetes have been replaced by recommendations in the Diabetes - type 2 (update) clinical guideline published in May 2008. Please note that the recommendations in this technology appraisal relating to type 1 diabetes have not changed.
Guidance documents
Guidance PDF format
Understanding NICE guidance PDF format
TA53 Arweiniad ar ddefnyddio analogau inswlin hirbarhaol ar gyfer trin clefyd siwgr - inswlin glargin: deall canllawiau NICE
TA53 Diabetes (types 1 and 2) - long acting insulin analogues: summary